A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama
A phase 1/2 trial of Elranatamab, Mezigdomide, Dexamethasone in multiple myeloma, run by Celgene, now recruiting.
Overview
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06988488 by Celgene, with 62 participants planned, started 2025-10-07 and due to reach its primary completion in 2027-05-31. Interventions recorded: Elranatamab, Mezigdomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Shares Elranatamab, Dexamethasone, Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Elranatamab, Dexamethasone, Multiple myeloma.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Elranatamab, Dexamethasone, Multiple myeloma.
- TrialMagnetisMM-3
Shares Elranatamab, Multiple myeloma.